This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease
≥18 years old, male or female;
Systemic Lupus Erythematosus (SLE), EULAR/ACR 2019 standard;
Sjogren's Syndrome (SS), 2016 ACR/EULAR standard;
Systemic Scleroderma (SSc), 2013 ACR/EULAR Standards;
Had previously received CAR T cell therapy;
patients with serious heart, liver, lung, blood system, endocrine system diseases, and the risk of participating in the trial is higher than the benefit judged by the researcher;
There is an active or uncontrollable infection that requires systemic treatment within 1 week prior to screening;
have previously received hematopoietic stem cell transplantation or solid organ transplantation (except corneal and hair transplantation), or have grade 2 or higher acute graft-versus-host disease (GVHD) within 2 weeks prior to screening;